---

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Detailed Clinical Note | 15 Marks | BPT - MGR University

---

1. DEFINITION

• The hallmark physiologic feature is irreversible (or minimally reversible) airflow obstruction, documented by spirometry: post-bronchodilator FEV1/FVC < 0.70.
• COPD encompasses two major clinicopathologic entities - Emphysema and Chronic Bronchitis - which commonly coexist in the same patient.

---

2. EPIDEMIOLOGY

• 4th leading cause of death worldwide; projected to become 3rd by 2030.
• Affects >15 million persons in the United States; estimated 480 million globally, projected to reach 592 million by 2050.
• 80% of COPD is attributable to cigarette smoking.
• Overall, 35-50% of heavy smokers develop COPD.
• More common in males, though female prevalence is rising.

---

3. ETIOLOGY AND RISK FACTORS

---

4. PATHOLOGY - COMPONENTS OF COPD

4a. Emphysema

• Defined as permanent, abnormal enlargement of air spaces distal to the terminal bronchioles with destruction of their walls, without obvious fibrosis.
• Types:
  • Centriacinar (Centrilobular) - Most common; destruction centered on respiratory bronchioles in upper lobes; strongly associated with cigarette smoking.
  • Panacinar (Panlobular) - Uniform destruction of the entire acinus; occurs in α1AT deficiency; predominantly lower lobe involvement.
  • Paraseptal (Distal Acinar) - Distributed along pleural margins; subpleural bullae formation; may cause spontaneous pneumothorax.

4b. Chronic Bronchitis

• Clinical definition: Productive cough for at least 3 consecutive months in at least 2 consecutive years (after excluding other causes).
• Pathological changes include:
  • Hyperplasia and hypertrophy of mucus-secreting submucosal glands in the trachea and large bronchi.
  • Increased Reid Index (ratio of gland thickness to bronchial wall thickness; normally ≤0.4; in chronic bronchitis >0.5).
  • Goblet cell metaplasia in the bronchial epithelium (including small airways).
  • Chronic inflammatory infiltrate (lymphocytes, neutrophils, macrophages).
  • Bronchiolar wall fibrosis and small airway inflammation (chronic bronchiolitis).

4c. Small Airway Disease

• Major site of increased airflow resistance is in airways ≤2 mm diameter.
• Changes include goblet cell metaplasia, smooth-muscle hypertrophy, mucosal edema, and fibrosis.
• Narrowing and dropout of small airways precede emphysematous destruction.

---

5. PATHOGENESIS

Protease-Antiprotease Imbalance (Key mechanism)

• Tobacco smoke and inhaled pollutants activate macrophages and neutrophils in the lung.
• These cells release proteolytic enzymes (elastase, matrix metalloproteinases - MMPs) that destroy elastin and connective tissue.
• Normally, Alpha-1 antitrypsin (α1AT) inhibits neutrophil elastase and protects alveolar walls.
• In COPD: Excess protease activity >> Antiprotease protection → Alveolar wall destruction → Emphysema.
• In α1AT deficiency, this imbalance is greatly amplified.

Oxidative Stress

• Cigarette smoke contains millions of free radicals per puff.
• Oxidants inactivate antiproteases (inactivating α1AT) and activate NF-κB, promoting inflammation.
• Oxidative stress promotes apoptosis of structural lung cells.

Inflammation

• Key cells: Neutrophils, Macrophages, CD8+ T-lymphocytes in the alveolar space.
• Neutrophil elastase is one of the most potent secretagogues, driving mucus hypersecretion.
• CD8+ T-cells (cytotoxic) are increased → promote lung cell apoptosis.
• Inflammatory mediators: IL-8, TNF-α, LTB4, IL-1β.

---

6. CLINICAL FEATURES

Symptoms

Signs on Physical Examination

• Barrel-shaped chest (increased AP diameter) due to air trapping
• Hyperresonance on percussion
• Reduced breath sounds bilaterally
• Prolonged expiratory phase with wheeze
• Pursed-lip breathing (increases intrinsic PEEP)
• Use of accessory muscles of respiration
• Tracheal tug (down-pull of trachea on inspiration)
• Hoover's sign - inward movement of lower ribs on inspiration
• Signs of cor pulmonale: raised JVP, peripheral edema, loud P2, parasternal heave

---

7. DIAGNOSIS

A. Spirometry (Gold Standard)

• Spirometry shows obstructive pattern: reduced FEV1, normal or near-normal FVC, reduced FEV1/FVC ratio.
• Airflow obstruction is NOT fully reversible with bronchodilators (distinguishes from asthma).
• Total Lung Capacity (TLC) and Residual Volume (RV) are increased (air trapping).
• DLCO (diffusing capacity for CO) is reduced in emphysema (loss of alveolar-capillary surface).

B. Arterial Blood Gas (ABG)

• Emphysema: PaO2 mildly reduced; PaCO2 normal (maintains ventilation - "Pink Puffer")
• Chronic bronchitis: PaO2 significantly reduced; PaCO2 elevated (hypoventilates - "Blue Bloater")
• Chronic respiratory failure: PaCO2 > 45 mmHg
• Compensatory metabolic alkalosis in chronic hypercapnia: pH change of 0.03 units per 10 mmHg change in PaCO2 (chronic).

C. Chest X-Ray

• Flattening of diaphragm (hyperinflation)
• Increased retrosternal airspace (lateral view)
• Decreased parenchymal markings / hyperlucency
• Bullae formation
• Large heart with pulmonary plethora in cor pulmonale

D. CT Chest

• Most sensitive for confirming emphysema, its pattern, and distribution.
• Demonstrates bullae, bronchiectasis, coexisting lung cancer.
• Low-dose annual CT: lung cancer screening in at-risk COPD smokers.

E. Other Investigations

• CBC: Polycythemia (raised Hct) in chronic hypoxemia; eosinophilia guides ICS use.
• Serum α1AT level: Screening in all COPD patients (especially young, non-smokers, lower lobe predominant).
• ECG/Echo: Cor pulmonale assessment - right ventricular hypertrophy, elevated pulmonary artery pressure.
• 6-Minute Walk Test: Functional exercise capacity assessment.

---

8. MANAGEMENT

A. Non-Pharmacological (Cornerstone)

1. Smoking cessation - Single most effective intervention; slows decline in FEV1.
2. Pulmonary rehabilitation - Exercise training + education; improves dyspnea, exercise tolerance, and quality of life.
3. Oxygen therapy - Long-term oxygen therapy (LTOT) for PaO2 ≤ 55 mmHg (or ≤ 60 mmHg with cor pulmonale/polycythemia); improves survival (≥15 hrs/day).
4. Vaccination: Annual influenza vaccine; pneumococcal vaccine.
5. Nutritional support: Manage malnutrition in severe COPD.
6. Breathing exercises: Pursed-lip breathing, diaphragmatic breathing (key for BPT).

B. Pharmacological Management (Stepped approach per GOLD)

C. Surgical Options (Selected Patients)

• Lung Volume Reduction Surgery (LVRS): Removes hyperinflated, poorly functioning tissue (usually upper-lobe emphysema); improves survival in selected patients.
• Bullectomy: Resection of large bullae compressing functional tissue.
• Lung transplantation: End-stage COPD with no other options.
• Bronchoscopic lung volume reduction: Endobronchial valves or coils.

---

9. ACUTE EXACERBATIONS OF COPD (AECOPD)

1. Controlled oxygen therapy: Target SpO2 88-92% (avoid hypercapnia).
2. Short-acting bronchodilators: Nebulized SABA + SAMA (salbutamol + ipratropium).
3. Systemic corticosteroids: Prednisolone 30-40 mg/day × 5 days; reduces recovery time.
4. Antibiotics: When purulent sputum or signs of infection (β-lactams, macrolides, fluoroquinolones).
5. Non-invasive positive pressure ventilation (NIPPV/BiPAP): For acute hypercapnic respiratory failure; reduces intubation and mortality.
6. Mechanical ventilation: For severe respiratory failure.

---

10. PHYSIOTHERAPY MANAGEMENT OF COPD (Relevant for BPT)

Assessment

• Respiratory rate, SpO2, chest expansion, breath sounds, sputum characteristics.
• Dyspnea scales: mMRC scale, Borg scale, CAT (COPD Assessment Test).
• Exercise tolerance: 6-minute walk test (6MWT).

Physiotherapy Interventions

1. Airway Clearance Techniques
   • Active Cycle of Breathing Techniques (ACBT)
   • Postural drainage (positioning for gravity-assisted drainage)
   • Percussion and vibration
   • Positive Expiratory Pressure (PEP) therapy
   • High-frequency chest wall oscillation (HFCWO)
   • Huffing (forced expiration technique)
2. Breathing Exercises
   • Pursed-lip breathing: Prevents small airway collapse; reduces respiratory rate; improves oxygenation.
   • Diaphragmatic breathing: Improves ventilatory efficiency.
   • Inspiratory muscle training (IMT): Using threshold IMT devices.
3. Pulmonary Rehabilitation Programme
   • Structured program: ≥ 8 weeks, 2-3 sessions/week.
   • Components: Aerobic exercise (walking, cycling), strength training, education, nutritional advice, psychological support.
   • Evidence-based benefits: Reduced dyspnea, improved exercise capacity, improved quality of life, fewer hospitalizations.
4. Exercise Prescription
   • Aerobic training: 60-80% of peak exercise capacity.
   • Strength training: Upper + lower limb resistance exercises.
   • Intensity guided by Borg scale (target 4-6/10 breathlessness).
5. Energy Conservation Techniques: Activity pacing, use of mobility aids (rollator walker reduces dyspnea on walking).
6. Patient Education: Inhaler technique, smoking cessation, vaccination, self-management of exacerbations.

---

11. COMPLICATIONS

• Cor pulmonale (right ventricular hypertrophy and failure due to pulmonary hypertension) - most common in chronic bronchitic type.
• Secondary polycythemia (due to chronic hypoxemia).
• Acute respiratory failure (especially during exacerbations).
• Spontaneous pneumothorax (rupture of paraseptal bullae/blebs).
• Lung cancer (significantly increased risk in smokers with COPD).
• Depression and anxiety (common comorbidities).
• Malnutrition and cachexia in severe disease.
• Osteoporosis (from steroid use + physical inactivity).

---

12. PROGNOSIS

• COPD is progressive and often fatal without intervention.
• BODE Index (Body mass index, airflow Obstruction, Dyspnea, Exercise tolerance) is a better predictor of mortality than FEV1 alone.
• Survival is improved by: smoking cessation, LTOT, LVRS (selected), pulmonary rehabilitation, triple inhaled therapy.
• Death is commonly due to cor pulmonale (right heart failure), acute respiratory failure, or lung cancer.

---

QUICK SUMMARY TABLE

---